This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

InOncology.com

CREATING BRIGHTER FUTURES THROUGH INNOVATIVE RESEARCH

We put patients at the heart of everything we do and we’re committed to our pipeline, and developing novel cancer agents to help improve lives

SHINING A LIGHT ON KEY AREAS OF ONCOLOGY

We’re committed to improving the lives of patients with lung cancer and addressing remaining unmet needs

IT’S ABOUT MAKING THE CONNECTIONS THAT COUNT

On 8-12th September we were at ESMO 2017 in Madrid, find out more about our newly released data, watch our webcast and download materials shared at ESMO.

FROM INFORMATION COMES ENLIGHTENMENT

We believe in continually learning, advancing and sharing knowledge, so that together we can enhance patient outcomes

LET’S COLLABORATE IN ONCOLOGY

We're passionate about seeking strong partnership to improve our understanding of cancer and transform patients lives

SEQUENCING TREATMENTS FOR PATIENTS

View this video to see how the landscape for treatment for EGFRM+ NSCLC has evolved, and how insights from afatinib clinical trials can inform treatment sequencing for patients with EGFRM+ NSCLC

We believe that when it comes to outsmarting cancer,

we’re brighter together.


Click and drag to connect the circles and illuminate the way forward or
SKIP TO HOMEPAGE

*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.